These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

740 related items for PubMed ID: 28533480

  • 1. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S, Salvestrini V, Carretta C, Genovese E, Rontauroli S, Zini R, Rossi C, Ruberti S, Bianchi E, Barbieri G, Curti A, Castagnetti F, Gugliotta G, Rosti G, Bergamaschi M, Tafuri A, Tagliafico E, Lemoli R, Manfredini R.
    Oncotarget; 2017 Jul 25; 8(30):49451-49469. PubMed ID: 28533480
    [Abstract] [Full Text] [Related]

  • 2. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.
    Blood Cells Mol Dis; 2014 Jul 25; 53(1-2):47-55. PubMed ID: 24629639
    [Abstract] [Full Text] [Related]

  • 3. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Polakova KM.
    Haematologica; 2018 Dec 25; 103(12):2016-2025. PubMed ID: 30049824
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
    Kayabasi C, Okcanoglu TB, Yelken BO, Asik A, Susluer SY, Avci CB, Saydam G, Gunduz C.
    Gene; 2017 Dec 30; 637():173-180. PubMed ID: 28942039
    [Abstract] [Full Text] [Related]

  • 7. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
    Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H, Lin A, Pellicano F, Hopcroft L, Su YL, Copland M, Holyoake TL, Kuo CJ, Bhatia R, Snyder DS, Ali H, Stein AS, Brewer C, Wang H, McDonald T, Swiderski P, Troadec E, Chen CC, Dorrance A, Pullarkat V, Yuan YC, Perrotti D, Carlesso N, Forman SJ, Kortylewski M, Kuo YH, Marcucci G.
    Nat Med; 2018 May 30; 24(4):450-462. PubMed ID: 29505034
    [Abstract] [Full Text] [Related]

  • 8. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
    Bamodu OA, Kuo KT, Yuan LP, Cheng WH, Lee WH, Ho YS, Chao TY, Yeh CT.
    Exp Cell Res; 2018 Sep 15; 370(2):519-530. PubMed ID: 30017934
    [Abstract] [Full Text] [Related]

  • 9. miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells.
    Rittavee Y, Artus J, Desterke C, Simanic I, de Souza LEB, Riccaldi S, Coignard S, Ijjeh Y, Hugues P, Bennaceur-Griscelli A, Turhan AG, Foudi A.
    Exp Hematol; 2023 Feb 15; 118():40-52. PubMed ID: 36535407
    [Abstract] [Full Text] [Related]

  • 10. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
    Li H, Liu L, Zhuang J, Liu C, Zhou C, Yang J, Gao C, Liu G, Sun C.
    Mol Genet Genomic Med; 2019 Sep 15; 7(9):e851. PubMed ID: 31373443
    [Abstract] [Full Text] [Related]

  • 11. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
    Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):597-605. PubMed ID: 25305453
    [Abstract] [Full Text] [Related]

  • 12. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
    Busch C, Mulholland T, Zagnoni M, Dalby M, Berry C, Wheadon H.
    Cell Commun Signal; 2023 Nov 29; 21(1):342. PubMed ID: 38031192
    [Abstract] [Full Text] [Related]

  • 13. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
    Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L, Bhatia R.
    Blood; 2013 Mar 07; 121(10):1824-38. PubMed ID: 23299311
    [Abstract] [Full Text] [Related]

  • 14. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
    Jin B, Wang C, Li J, Du X, Ding K, Pan J.
    Clin Cancer Res; 2017 Feb 01; 23(3):789-803. PubMed ID: 27492973
    [Abstract] [Full Text] [Related]

  • 15. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H.
    Biomed Pharmacother; 2020 Sep 01; 129():110390. PubMed ID: 32563150
    [Abstract] [Full Text] [Related]

  • 16. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X.
    Oncotarget; 2014 Sep 30; 5(18):8637-50. PubMed ID: 25226617
    [Abstract] [Full Text] [Related]

  • 17. Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
    Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R, Pellicano F, Guenther C, Gallipoli P, Cruz M, Dunn K, Jorgensen HG, Cassels JE, Hamilton A, Crossan A, Sinclair A, Holyoake TL, Vetrie D.
    Cancer Discov; 2016 Nov 30; 6(11):1248-1257. PubMed ID: 27630125
    [Abstract] [Full Text] [Related]

  • 18. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K, Mahon FX, Josselin M, Jeanneteau M, Turcq B, Belloc F.
    Exp Hematol; 2012 May 30; 40(5):367-78.e2. PubMed ID: 22240609
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells.
    Agatheeswaran S, Pattnayak NC, Chakraborty S.
    Sci Rep; 2016 Sep 02; 6():32493. PubMed ID: 27586591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.